Evidence-based evaluation of drug gene studies in Chinese patients with epilepsy

YANG Chun-song; WANG Yan-mei; ZHANG Ling-li; YU Dan

doi:10.3969/j.issn.1672-8157.2017.05.001

Abstract：Objective: To systematically review the current studies of gene-based drug treatment in Chinese epilepsy patients in order to provide evidence for the treatment of epilepsy. Methods: We searched several databases including CBM, CNKI, VIP and Wanfang databases from inception to January 2017. Papers focusing on the association between related genes and antiepileptic drug resistance, drug efficacy, adverse drug reactions, serum drug concentration and drug dosage were included and descriptively analyzed. Results: A total of 49 articles published from 2007 to 2016 were included. The overall quantity was increasing. Study samples varied between 2 and 654 cases. Genes that could affect the blood serum concentration of drugs were UGTlA4, UGT1A6, CYP3A4, CYP3A5, CYP2C9, CYP2C19, ABCC2, and UGT2B7. In addition, SCN1A, ABCB1, CYP2C19 and MDR1 could affect the efficacy of drugs. The HLA and EPHX1 were positively associated with adverse drug reactions. Genes that could affect the drug dose were ABCC2-24C>T and CYP2C19. Conclusion: The research of pharmacogenomics researches on anti-epileptic drugs developed rapidly, and the related genes were diverse and complicated. However, the sample size was small. Few studies used control group in study design. And there was rare research on the relationship between genes and adverse drug reactions and drug efficacy. Most of the studies were needed to be validated by further clinical studies with high-quality and large samples.